Jill M. Quigley Sells 6,240 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley sold 6,240 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total transaction of $35,692.80. Following the transaction, the director now owns 8,760 shares in the company, valued at approximately $50,107.20. This trade represents a 41.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jill M. Quigley also recently made the following trade(s):

• On Monday, January 6th, Jill M. Quigley sold 8,760 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $5.79, for a total transaction of $50,720.40.

Terns Pharmaceuticals Stock Down 0.7 %

NASDAQ TERN traded down $0.04 during trading hours on Monday, hitting $5.71. 1,252,259 shares of the stock were exchanged, compared to its average volume of 1,424,849. The company has a market cap of $485.00 million, a price-to-earnings ratio of -4.84 and a beta of -0.31. Terns Pharmaceuticals, Inc. has a 12-month low of $4.32 and a 12-month high of $11.40. The stock has a 50-day moving average of $6.35 and a 200 day moving average of $7.41.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. On average, equities research analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TERN. HC Wainwright reaffirmed a “neutral” rating and issued a $7.50 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. BMO Capital Markets restated an “outperform” rating and issued a $26.00 price target (up previously from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. Oppenheimer increased their price objective on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 4th. Finally, JMP Securities reissued a “market outperform” rating and issued a $20.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.30.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Terns Pharmaceuticals during the 3rd quarter worth $48,000. Sio Capital Management LLC purchased a new stake in Terns Pharmaceuticals during the third quarter worth about $83,000. Entropy Technologies LP acquired a new position in Terns Pharmaceuticals during the third quarter worth about $106,000. Bleakley Financial Group LLC increased its holdings in Terns Pharmaceuticals by 26.0% in the third quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company’s stock valued at $111,000 after buying an additional 2,751 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Terns Pharmaceuticals by 78.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,535 shares of the company’s stock valued at $113,000 after acquiring an additional 5,935 shares during the period. Institutional investors and hedge funds own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.